Innovation
is our nature

Discover our research

More than Science

The B20 Healthcare & Life Sciences, guided by Sergio Dompé, underscores the strategic role of scientific research with a global video campaign

More

Drug Discovery: our new approach

Our team of researchers aims at identifying increasingly effective and selective compounds to either improve existing drugs and develop new ones that can act on diseases that are still without a cure.

discover more

Dompé in the media

Read the articles

Dompé Foundation

We invest in the Life Sciences Education of young talents through scholarships and grants. By involving top innovative universities, its ambition is to contribute to the development of the careers of the future.

discover more

Supercomputers against coronavirus

E4C aims at leveraging EU’s supercomputing resources coupling them with some of the continent’s best life-science research labs to counter international pandemics faster and more efficiently

Discover More

We are hiring

People are our most precious asset and that is why we promote their professional development.

CHECK OUT OUR OPEN POSITIONS

Neurotrophins

Dompé’s Cenegermin Nerve Growth Factorbased therapy was awarded Breakthrough Therapy designation by the US Food and Drug Administration (FDA) and marketing authorized in Europe, US and China.

discover more

Dompé Holdings

Bringing vision into medium and long term investment

discover more

Partners

Every day we develop new collaborations: we partner with unique talents and minds to discover and produce breakthrough therapies

discover more

Research, development and production contributing to innovation

Alongside our manufacturing activities, our hub in L’Aquila also accommodates a number of research facilities covering the whole Drug Discovery process for small molecules and biotech drugs, from the early stage to clinical development and patient administration.

Discover our production hub

8 production lines

7 synthesis, 1 biotech

60 million

manufactured packages per year

CDMO facility

synthesis and biotech

27 clinical trials

over 200 patients

Dompé logo

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153